Olgu Sunumu
BibTex RIS Kaynak Göster
Yıl 2022, Cilt: 6 Sayı: 4, 535 - 536, 01.04.2022
https://doi.org/10.28982/josam.875764

Öz

Kaynakça

  • 1. Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016;5:97–104. doi: 10.1016/j. msard.2015.11.006.
  • 2. Oh J, O’Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177-90. doi: 10.2147/TCRM.S30947.
  • 3. Abdalla AE, Lambert N, Duan X, Xie J. Interleukin-10 Family and Tuberculosis: An Old Story Renewed. Int J Biol Sci. 2016;27;12(6):710-7. doi: 10.7150/ijbs.13881.
  • 4. Sirbu CA, Dantes E, Plesa CF, Axelerad AD, Ghinescu MC. Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review Medicina. 2020;56:1-7. doi: 10.3390/medicina560402025.
  • 5. Zhou X, Yang J, Zhang Z, Zhang L, Zhu B, Lie L, et al. Different Signaling Pathways Define Different Interferon-Stimulated Gene Expression during Mycobacteria Infection in Macrophages. Int. J. Mol. Sci. 2019;20:1-14. doi: 10.3390/ijms20030663.
  • 6. Köseoğlu M, Gözübatık-Çelik RG, Kürtüncü M. A case report with tuberculous meningitis during fingolimod treatment. 2020;46:102450. doi: 10.1016/j.msard.2020.102450.

A case of multiple sclerosis diagnosed with tuberculosis during teriflunomide therapy

Yıl 2022, Cilt: 6 Sayı: 4, 535 - 536, 01.04.2022
https://doi.org/10.28982/josam.875764

Öz

A case of pulmonary tuberculosis (TB) in a patient with multiple sclerosis (MS) receiving teriflunomide is described. A 56-year-old woman with MS started interferon beta-1a treatment in 2009. Due to side effects, her physician switched her to glatiramer acetate. Over the last three years, she opted not to continue the glatiramer acetate. At the end of 2017, her symptoms reappeared, and her radiological and clinical examination showed disease progression. Teriflunomide (14 mg/day) treatment was started, and in the 15th month of teriflunomide use, a rash on the skin, coughing, night sweating fits, weakness and back pain developed. She was diagnosed with pulmonary TB based on pulmonary examination. Her purified protein derivative (PPD) score was 22. Anti-TB therapy was initiated immediately. At last visit in January 2020, TB was discovered. Her blood tests were within normal limits. Her expanded disability status score (EDSS) score was 2.5. Subcutaneous glatiramer acetate was re-initiated. A rare case of pulmonary TB under teriflunomide use is described in this case. Teriflunomide therapy should be considered in cases in which latent TB may be re-activated.

Kaynakça

  • 1. Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016;5:97–104. doi: 10.1016/j. msard.2015.11.006.
  • 2. Oh J, O’Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177-90. doi: 10.2147/TCRM.S30947.
  • 3. Abdalla AE, Lambert N, Duan X, Xie J. Interleukin-10 Family and Tuberculosis: An Old Story Renewed. Int J Biol Sci. 2016;27;12(6):710-7. doi: 10.7150/ijbs.13881.
  • 4. Sirbu CA, Dantes E, Plesa CF, Axelerad AD, Ghinescu MC. Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review Medicina. 2020;56:1-7. doi: 10.3390/medicina560402025.
  • 5. Zhou X, Yang J, Zhang Z, Zhang L, Zhu B, Lie L, et al. Different Signaling Pathways Define Different Interferon-Stimulated Gene Expression during Mycobacteria Infection in Macrophages. Int. J. Mol. Sci. 2019;20:1-14. doi: 10.3390/ijms20030663.
  • 6. Köseoğlu M, Gözübatık-Çelik RG, Kürtüncü M. A case report with tuberculous meningitis during fingolimod treatment. 2020;46:102450. doi: 10.1016/j.msard.2020.102450.
Toplam 6 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Nöroloji ve Nöromüsküler Hastalıklar
Bölüm Olgu sunumu
Yazarlar

Rabia Gökçen Gözübatık Çelik 0000-0002-8186-8703

Musa Öztürk 0000-0001-9652-384X

Yayımlanma Tarihi 1 Nisan 2022
Yayımlandığı Sayı Yıl 2022 Cilt: 6 Sayı: 4

Kaynak Göster

APA Gözübatık Çelik, R. G., & Öztürk, M. (2022). A case of multiple sclerosis diagnosed with tuberculosis during teriflunomide therapy. Journal of Surgery and Medicine, 6(4), 535-536. https://doi.org/10.28982/josam.875764
AMA Gözübatık Çelik RG, Öztürk M. A case of multiple sclerosis diagnosed with tuberculosis during teriflunomide therapy. J Surg Med. Nisan 2022;6(4):535-536. doi:10.28982/josam.875764
Chicago Gözübatık Çelik, Rabia Gökçen, ve Musa Öztürk. “A Case of Multiple Sclerosis Diagnosed With Tuberculosis During Teriflunomide Therapy”. Journal of Surgery and Medicine 6, sy. 4 (Nisan 2022): 535-36. https://doi.org/10.28982/josam.875764.
EndNote Gözübatık Çelik RG, Öztürk M (01 Nisan 2022) A case of multiple sclerosis diagnosed with tuberculosis during teriflunomide therapy. Journal of Surgery and Medicine 6 4 535–536.
IEEE R. G. Gözübatık Çelik ve M. Öztürk, “A case of multiple sclerosis diagnosed with tuberculosis during teriflunomide therapy”, J Surg Med, c. 6, sy. 4, ss. 535–536, 2022, doi: 10.28982/josam.875764.
ISNAD Gözübatık Çelik, Rabia Gökçen - Öztürk, Musa. “A Case of Multiple Sclerosis Diagnosed With Tuberculosis During Teriflunomide Therapy”. Journal of Surgery and Medicine 6/4 (Nisan 2022), 535-536. https://doi.org/10.28982/josam.875764.
JAMA Gözübatık Çelik RG, Öztürk M. A case of multiple sclerosis diagnosed with tuberculosis during teriflunomide therapy. J Surg Med. 2022;6:535–536.
MLA Gözübatık Çelik, Rabia Gökçen ve Musa Öztürk. “A Case of Multiple Sclerosis Diagnosed With Tuberculosis During Teriflunomide Therapy”. Journal of Surgery and Medicine, c. 6, sy. 4, 2022, ss. 535-6, doi:10.28982/josam.875764.
Vancouver Gözübatık Çelik RG, Öztürk M. A case of multiple sclerosis diagnosed with tuberculosis during teriflunomide therapy. J Surg Med. 2022;6(4):535-6.